2018
AllerGene AI Therapeutics was founded with a clear vision: to bridge the gap between artificial intelligence and clinical immunology. Our journey began in a small research lab dedicated to mapping cellular response patterns using neural networks.
2021
We successfully pioneered our first next-generation in vivo cellular immunotherapy platform. This breakthrough allowed for precisely targeted therapeutic solutions that adapt to individual genetic markers in real-time.
2024
Expanding our commitment to medical breakthroughs, we established specialized biotech hubs across three continents. Our cross-functional teams now lead the industry in developing advanced therapeutic solutions for complex immunological disorders.
2026
Looking forward, AllerGene continues to push the boundaries of AI integration in therapeutics. Our ongoing research seeks to automate the discovery of novel cell therapies, making life-changing treatments more accessible than ever before.
Core Methodology
The Precision of In Vivo Cellular Programming
[FIG 01] Targeted Viral Vector Delivery Mechanism
Our proprietary platform utilizes advanced AI to design localized delivery vehicles that program immune cells directly within the patient’s body, bypassing the need for complex ex vivo manufacturing.
[FIG 02] Genomic Sequence Validation
Scalable AI-Driven Synthesis
By integrating machine learning algorithms with synthetic biology, we accelerate the discovery of optimal therapeutic candidates from years to weeks.
94%
Targeting Accuracy Increase
[FIG 04] Automated Synthesis Workflow Architecture
[FIG 03] Intra-body Cellular Interaction